Somatostatin is a peptide hormone and neural signaling molecule that primarily inhibits the release of other hormones and secretions. It is produced in the hypothalamus, other regions of the nervous system, the pancreas, and the gastrointestinal tract. Its effects include suppressing growth hormone secretion, regulating insulin and glucagon release, and reducing gastrointestinal secretion and motility. Naturally occurring somatostatin acts briefly; longer-acting synthetic analogues are used to treat several endocrine disorders and neuroendocrine tumors.
Structure and production
In humans, somatostatin is encoded by the SST gene. Its initial precursor, preprosomatostatin, is processed into two main biologically active forms:
- Somatostatin-14, containing 14 amino acids.
- Somatostatin-28, containing 28 amino acids, with the somatostatin-14 sequence forming its final 14 residues.
Both forms contain an internal disulfide bond that creates a cyclic portion essential to their biological activity. Their relative abundance varies among tissues. Somatostatin-14 is prominent in the nervous system and pancreatic islets, whereas somatostatin-28 is particularly important in the intestine.
Major sources include hypothalamic neurons, inhibitory neurons distributed throughout the central nervous system, pancreatic islet delta cells, and gastrointestinal endocrine cells known as D cells. Somatostatin can act as a circulating hormone, as a local regulator of nearby cells, or as a neural messenger. Consequently, its physiological effects cannot be understood solely from its concentration in the bloodstream.
Receptors and signaling
Somatostatin acts through five receptor subtypes, commonly designated SSTR1 through SSTR5. These belong to the G protein–coupled receptor family and are expressed in different combinations across normal tissues and tumors.
The receptors couple principally to inhibitory G proteins. Their activation can reduce adenylyl cyclase activity and intracellular cyclic AMP, inhibit calcium entry, and increase potassium conductance. Depending on the cell, these changes reduce electrical excitability and the release of stored hormones or other secretory products.
Receptor activation can also influence pathways involved in cell proliferation. These effects help explain why some somatostatin analogues can slow the growth of certain tumors as well as suppress hormone secretion. The response depends on receptor subtype, receptor abundance, and the biological characteristics of the target tissue.
Physiological functions
Hypothalamus and pituitary gland
Hypothalamic somatostatin reaches the anterior pituitary gland through the hypothalamic–pituitary portal circulation. It inhibits the secretion of growth hormone, opposing the stimulatory action of growth hormone–releasing hormone.
The interaction between these signals contributes to the pulsatile pattern of growth hormone secretion. Somatostatin is therefore a regulator of growth-related endocrine activity rather than simply an inhibitor of body growth. It also inhibits thyroid-stimulating hormone secretion.
Pancreatic islets
Within pancreatic islets, somatostatin released by delta cells acts locally on neighboring endocrine cells. It inhibits both insulin release from beta cells and glucagon release from alpha cells.
Because insulin generally lowers blood glucose while glucagon raises it, somatostatin does not have a single, uniformly glucose-lowering or glucose-raising effect. Its net metabolic effect depends on nutritional state, the balance of pancreatic hormone secretion, and other physiological signals. This local regulation contributes to glucose homeostasis.
Gastrointestinal tract
Somatostatin broadly restrains digestive activity. Its actions include inhibition of gastric acid secretion, suppression of several gastrointestinal hormones, and reduction of pancreatic exocrine secretion. It can also slow gastrointestinal transit, inhibit gallbladder contraction, and reduce splanchnic blood flow.
In the stomach, D-cell somatostatin participates in local feedback control of acid production. It inhibits gastrin release and also acts on other cells involved in acid secretion. Acidification of the stomach contents helps stimulate this inhibitory feedback.
Nervous system
Somatostatin functions as a neuropeptide in the brain and spinal cord. It is expressed by several classes of inhibitory neurons, including interneurons in the cerebral cortex and hippocampus. These cells participate in the regulation of neuronal circuits.
The term “somatostatin-positive neuron” identifies a cell by its expression of the peptide; it does not imply that somatostatin is the cell’s only signaling substance. Many such neurons also release the inhibitory neurotransmitter GABA.
Pharmacological use
Natural somatostatin is rapidly broken down, with a plasma half-life of only a few minutes. This short duration limits its usefulness for sustained treatment and generally requires intravenous infusion when the native peptide is used.
Synthetic somatostatin analogues, including octreotide, lanreotide, and pasireotide, persist longer and differ in their receptor-binding profiles. Some are available in long-acting formulations. They are not interchangeable in all indications.
Established clinical applications include:
- Acromegaly: suppression of excessive growth hormone secretion, with a resulting reduction in insulin-like growth factor 1.
- Selected neuroendocrine tumors: control of hormone-related symptoms, such as flushing and secretory diarrhea, and, for particular tumors and medicines, slowing of tumor progression.
- Cushing disease: pasireotide can suppress adrenocorticotropic hormone secretion from a pituitary tumor in selected circumstances.
- Acute variceal bleeding: somatostatin or certain analogues are used in some clinical settings to reduce portal inflow as part of treatment.
Adverse effects reflect the same inhibitory actions responsible for therapeutic benefit. They can include gastrointestinal discomfort, altered bowel habits, impaired fat digestion, gallstones, and disturbances of blood glucose. Either hyperglycemia or hypoglycemia may occur, depending on the medicine and clinical context.
Somatostatin-producing tumors and receptor-based imaging
A somatostatinoma is a rare neuroendocrine tumor that produces somatostatin, most often arising in the pancreas or duodenum. When sufficiently large amounts of biologically active hormone are released, the associated syndrome can include diabetes mellitus, gallstones, and fatty stools caused by impaired digestion. Many tumors identified as somatostatin-producing do not cause the complete syndrome.
Somatostatin receptors also have diagnostic importance independently of somatostatin secretion. Many well-differentiated neuroendocrine tumors express these receptors, allowing radiolabeled somatostatin analogues to be used in nuclear medicine imaging. Receptor-targeted compounds can also deliver therapeutic radiation, an approach called peptide receptor radionuclide therapy.
Receptor expression does not establish that a tumor secretes somatostatin, and the absence of strong receptor uptake does not exclude every neuroendocrine tumor. Receptor imaging and hormone measurements assess different biological properties.
Discovery
Somatostatin was isolated and characterized from hypothalamic tissue in 1973 during research into the control of pituitary growth hormone secretion. Its name reflects this original growth hormone–inhibiting action. Subsequent identification in pancreatic and gastrointestinal cells established its broader role as a regulator of endocrine secretion, digestion, and neural signaling.